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Background: Gene mutations in the RAS family rule out metastatic colorectal carcinomas (mCRCs) from anti-EGFR therapies.
Methods: We report a retrospective analysis by Sequenom Massarray and fast COLD-PCR followed by Sanger sequencing on
240 mCRCs.
Results: By Sequenom, KRAS and NRAS exons 2-3-4 were mutated in 52.9% (127/240) of tumours, while BRAF codon 600
mutations reached 5% (12/240). Fast COLD-PCR found extra mutations at KRAS exon 2 in 15/166 (9%) of samples, previously
diagnosed by Sequenom as wild-type or mutated at RAS (exons 3-4) or BRAF genes. After UDG digestion results were reproduced
in 2/12 analysable subclonally mutated samples leading to a frequency of true subclonal KRAS mutations of 1.2% (2.1% of the
previous Sequenom wild-type subgroup). In 10 out of 12 samples, the subclonal KRAS mutations disappeared (9 out of 12) or
turned to a different sequence variant (1 out of 12).
Conclusions: mCRC can harbour coexisting multiple gene mutations. High sensitivity assays allow the detection of a small subset
of patients harbouring true subclonal KRAS mutations. However, DNA changes with mutant allele frequencies o3% detected in
formalin-fixed paraffin-embedded samples may be artifactual in a non-negligible fraction of cases. UDG pre-treatment of DNA is
mandatory to identify true DNA changes in archival samples and avoid misinterpretation due to artifacts.
The threshold of ‘precision medicine’ in oncology is continuously
rising. In the past few years, many molecular players involved in
oncogenesis have been exploited as potential drug targets in the
ever-growing approach of patient-tailored care (Jurgensmeier et al,
2014; Stevens and Rodriguez, 2015). The results of several clinical
trials (Harbeck and Wuerstlein, 2013; Landi and Cappuzzo, 2014;
Khattak et al, 2015) have shown that often only specific subgroups
of patients benefit from molecular-targeted treatments. Thus,
the development of highly sensitive and specific companion
diagnostic tests is needed to improve the characterisation of the
responsive patients and to intercept molecular alterations with
negative or positive predictive value (Dienstmann et al, 2015;
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Hovelson et al, 2015; Zhao et al, 2015). Moreover, in the current
era of increasing healthcare costs colliding with shrinking budgets,
the precise identification of who could benefit the most from a
specific treatment is of paramount importance.
In colorectal tumours, the subset of patients amenable to targeted
therapies with anti-EGFR drugs underwent few revisions (Van
Cutsem et al, 2015) as new detrimental somatic point mutations have
been found to hamper the response to these treatments, in addition
to the more common mutations at codons 12 and 13 of KRAS. The
additional mutations span codons 61, 117 and 146 of KRAS and
codons 12, 13, 61, 117 and 146 of NRAS (extended RAS).
Nevertheless, both the improved understanding of tumour
heterogeneity and the high sensitivity of the assays introduced in
molecular diagnostics open new questions focusing on which
cutoff value makes an alteration a significant marker leading to a
different outcome or a different clinical response. Few and
contradictory data are available on the predictive role of a low
mutational load in tumour samples (defined as a low number of
neoplastic cells harbouring a specific mutation) compared to wild-
type lesions (Dono et al, 2013; Kimura et al, 2012; Laurent-Puig
et al, 2015; Molinari et al, 2011; Normanno et al, 2015; Tougeron
et al, 2013; Van Cutsem et al, 2015). To date, these questions are
being explored especially in the field of lung adenocarcinomas
(Wang et al, 2014) and more recently facing the issue of
quantitatively monitoring the emergence of KRAS mutations in
liquid biopsy samples of metastatic colorectal carcinoma (mCRC)
patients treated with anti-EGFR drugs (Toledo et al, 2017).
In the present study, we investigated the real nature and true
incidence of subclonal mutations detected in formalin-fixed paraffin-
embedded (FFPE) samples by increasing assay sensitivities (0.1–5%).
MATERIALS AND METHODS
Patients. The study included 240 mCRC patients whose tumour
was analysed at our institution in 2014 to select possible candidates
for anti-EGFR therapy based on their mutational profile. As a local
reference laboratory for the diagnostic mutational screening in
solid tumours since 2010, we have been successfully participating
to several EQA schemes of the European Society of Pathology and
of the Italian Association of Medical Oncologists/Italian Society of
Pathological Anatomy and Cytology (AIOM-SIAPEC-IAP) for
KRAS and BRAF (data not shown).
The cohort was composed of 108 women and 132 men, and the
median age at diagnosis was 62 (range: 34–84) and 67 years (range:
22–92), respectively. Tumour grading and staging data, according
to World Health Organization and AJCC Staging criteria (VII
Edition, 2010), were available for the 160 patients treated at our
Institution (Table 1). The tissues analysed were mainly histological
samples from primary CRCs (98%), locally resected at diagnosis
(81%) or at relapse (6%). Most cases displayed moderate-to-low
differentiation (92.6% G2-G3), locally advanced disease (94.5%
pT3-4), lymph nodal involvement (74.4% pN1-2) and perineural
and/or vascular invasion (78.4%). The series also included distant
metastases (13% of the cases, including seven pulmonary, 17 liver,
two bone, one peritoneal, one cerebral and one pelvic metastases).
The study was submitted to and approved by the Ethic
Institutional Review Board (IRB) responsible for ‘Biobanking and
use of human tissues for experimental studies’ of the Department
of Medical Sciences at the University of Turin. The IRB approved a
verbal consent procedure due to the retrospective design of the
study, which had no effect on their care.
Material selection. We retrieved the 240 DNA samples that were
earlier banked when the diagnostic analysis was performed on one
representative FFPE tumour block. For six selected cases additional
FFPE samples corresponding to alternative tumour blocks of the
primitive tumour and/or regional lymph-node/distant metastases
were submitted to DNA extraction.
In all cases a selection of the tumour area was performed as
previously described (Mariani et al, 2015). Morphological ade-
quacy criteria were derived from the Biogate portal (https://
testbiomolecolari.it/) of the AIOM-SIAPEC-IAP. Specimens were
Table 1. Clinicopathological features of tumour specimens in relation to KRAS, NRAS and BRAF gene mutation status
KRAS mut n (%) NRAS mut n (%) BRAF mut n (%) RAS/BRAF WT n (%) Total n (%)
Sex
F 52 (48.1) 6 (5.6) 10 (9.3)a 40 (37.0) 108 (45.0)
M 61 (46.2) 8 (6.1) 2 (1.5) 61 (46.2) 132 (55.0)
Sub total 113 (47.1) 14 (5.8) 12 (5.0) 101 (42.1) 240 (100)
Age (years)
Median 64 68 65,5 63,5 —
Range 34–84 40–87 51–73 22–92 —
Sub total 101 (47.2) 13 (6.1) 10 (4.7) 90 (42.0) 214 (100)
G
1–2 57 (48.7) 5 (4.3) 1 (0.9) 54 (27.3) 117 (71.8)
3–4 21 (45.6) 4 (8.7) 5 (10.9)a 16 (34.8) 46 (28.2)
Sub total 78 (47.8) 9 (5.5) 6 (3.7) 70 (42.9) 163 (100)
pT
1–2 5 (55.5) 1 (11.1) 0 (0) 3 (0) 9 (5.5)
3–4 73 (47.4) 8 (5.2) 6 (3.4) 67 (43.5) 154 (94.5)
Sub total 78 (47.8) 9 (5.5) 6 (3.7) 70 (42.9) 163 (100)
pN
0 19 (46.3) 3 (7.3) 2 (4.9) 17 (41.5) 41 (25.6)
1 36 (56.3) 3 (4.7) 0 (0) 25 (39.1) 64 (40.0)
2 21 (38.2) 2 (3.6) 4 (7.3) 28 (50.9) 55 (34.4)
Sub total 76 (47.5) 8 (5.0) 6 (3.8) 70 (43.7) 160 (100)
Vascular and/or perineural invasion
Yes 52 (44.8) 6 (5.2) 4 (3.4) 54 (41.7) 116 (78.4)
No 17 (53.1) 2 (6.3) 1 (3.1) 12 (37.5) 32 (21.6)
Abbreviations: mut¼mutated; WT¼wild-type; F¼ female; M¼male.
aBRAF mutations are significantly more prevalent in female patients (F) and G3-G4 tumours rather than in males (M) and G1-G2 tumours (P¼ 0.013).
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recorded as adequate when tumour enrichment was higher than
the 50% and at least 100 neoplastic cell were present.
DNA extraction. DNA extraction from FFPE tissues was
performed as previously described (Mariani et al, 2015) and
concentrations/purity were measured by a Nanodrop 1000
spectrophotometer (Thermo Fisher Scientific, Wilmington, DE,
USA).
Mass spectrometry technology for DNA sequencing. The DNAs
were amplified according to the manufacturer’s instructions on a
Labcycler (SensoQuest GmbH, Germany), using the CE-IVD
Myriapod Colon Status kit (Diatech Pharmacogenetics, Jesi,
Italy) based on a multiplex-PCR. The amplified DNAs were
submitted to a Shrimp Alkaline Phosphatase digestion (SAP
reaction) to remove the excess of free nucleotides. Finally,
the purified DNAs underwent a reaction of primer extension
(iPLEX) with oligonucleotides flanking each gene position under
study and with dideoxynucleotide terminators of known mass to
discriminate wild-type from mutated genotypes, by using a matrix-
assisted laser desorption ionisation time-of-flight mass spectro-
metry. Amplified DNAs were dispensed on a supplied solid chip
prior to be scanned on a MassARRAY instrument (Sequenom Inc,
San Diego, CA, USA).
The Myriapod Colon Status kit identifies 58, 54, 23 and 66
nucleotide substitutions in the KRAS, NRAS, BRAF and PIK3CA
genes, respectively. Among them, the mutations related to the
clinical response to anti-EGFR treatments are those affecting
codons 12, 13, 59, 61, 117 and 146 in both KRAS and NRAS, while
the mutations at codon 600 of BRAF have a prognostic
significance. This assay also explores mutations at multiple codons
of the PIK3CA gene.
Fast COLD-PCR followed by Sanger Sequencing for codons 12
and 13 of KRAS. The fast COLD-PCR for the exon 2 of KRAS
followed by Sanger Sequencing was applied to all samples
considered wild-type by Sequenom at exon 2 of KRAS and to a
subset of those KRAS (exon 2) mutated. The assay was used: (1) to
confirm the Sequenom results; (2) to identify the presence and
incidence of minor tumour clones undetectable by the standard
methods; (3) to determine the real nature of the subclonal
mutations. In brief, 30 ng of DNA/reaction were added to
fast COLD-PCR reagents and preliminary submitted to treatment
at 37 1C for 300 in the presence or absence of 0.5 U of Uracil-DNA-
Glycosylase (UDG, Thermo Fisher) (Do and Dobrovic, 2012).
The protocol of the fast COLD-PCR analysis was derived
from Mancini et al (Mancini et al, 2010) in absence of fluorophores
in the reagent mix, under conditions modified as follows: 20
cycles of standard PCR (95.0 1C 8’’, 60.0 1C 30’’, 72.0 1C 30’’)
followed by 35 cycles of COLD-PCR (82.5 1C 8’’, 58.0 1C 30’’,
72.0 1C 30’’). The denaturation step was set at a critical dissociation
temperature, favouring the amplification of the mutated
sequences. The amplified products were then submitted to Sanger
Sequencing.
PCR followed by Sanger Sequencing for KRAS, NRAS and BRAF
mutational analysis. Targeted-PCRs were followed by Sanger
Sequencing (Sanger et al, 1977) to confirm the somatic gene
mutations with clinical significance demonstrated by Sequenom.
Sanger Sequencing was also applied to PCR products of the fast
COLD-PCR.
Reagent mixes for targeted-PCRs contained 70 ng of genomic
DNA, 1 buffer, 1.5mM of MgCl2, 200 mM of dNTPs, 1.2 U of
AmpliTaq Gold DNA Polymerase (Invitrogen, Carlsbad, CA, USA)
and 0.5mM of each couple of primers, in a final volume of 50 ml.
KRAS and NRAS primers were designed using the software
Primer3 (http://frodo.wi.mit.edu/primer3/) on the human genomic
sequence (http://www.ncbi.nlm.nih.gov/gene) (ID:3845 and
ID:7812, respectively) and are available upon request. The BRAF
primers were derived from Moroni et al (Moroni et al, 2005), and
generated amplicons of 228 bp. PCR conditions consisted of a
unique touchdown scheme (an annealing decrease of 3.0 1C each 3
cycles starting from 64.0 1C down to 57.0 1C) that was repeated for
44 cycles. The purified products of both targeted- and fast COLD-
PCR (see above) were then submitted to a cycle sequencing
reaction, as previously described (Mariani et al, 2015). The
Chromas software (www.technelysium.com.au) was used for
sequence analysis.
Sensitivities of the assays. The declared sensitivity of the
Myriapod Colon Status kit varied from 2.5 to 10%, depending on
the mutation under study. Homemade reactions were designed to
determine the sensitivities of Sanger Sequencing when preceded by
a standard targeted-PCR (KRAS and BRAF) or by a fast COLD-
PCR (KRAS). Mutated DNA extracted from specific cell lines were
progressively diluted in blood-derived DNA of a healthy donor.
Briefly, the A549 cell line, homozygous for the KRAS p.G12S
(p.Gly12Ser) mutation, and the HT29, heterozygous for the BRAF
p.V600E (p.Val600Glu) mutation, were purchased from the ATCC
(LGC Standards S.r.l., Sesto San Giovanni, Milan, Italy) and tested
at different dilution in the wild-type sample DNA. The described
mutation at KRAS was detected by Sanger Sequencing at a
sensitivity near to 10% and 0.1% starting from products of
standard targeted-PCRs and fast COLD-PCRs, respectively
(Supplementary Figure 1A). The sensitivity for the BRAF mutation
was set at 5% (Supplementary Figure 1B).
Statistics. Pearson’s w2-test corrected if necessary for the Fisher’s
exact test was applied to 2 2 Contingency Tables to compare the
mutation frequencies: (1) among patients with different character-
istics; (2) among tumour DNAs analysed with different degree of
enrichment, and with alternative protocols of PCR before
sequencing (www.openepi.com). P-valueso0.05 were considered
statistically significant.
RESULTS
KRAS/NRAS/BRAF/PIK3CA mutation frequencies by Sequenom
in mCRCs. By Sequenom analysis we demonstrated a
point mutation (exon 2 of KRAS) in 40.0% (96/240) of mCRC
patients (Figure 1A), in line with results previously obtained
by pyrosequencing (Mariani et al, 2015). The extended
survey identified 43 additional patients (43/240, 17.9%) with
further tumour DNA mutations, mutually exclusive and distrib-
uted as follows: 17/240 (7.1%) at exons 3-4 of KRAS, 14/240 (5.8%)
at exons 2-3-4 of NRAS and 12/240 (5.0%) at codon 600 of
BRAF. Overall, the ‘extended RAS’ mutated samples represented
21.5% (31/144) of those samples defined as wild-type until
the ASCO guideline update (Allegra et al, 2016). Finally, by
Sequenom, for the codons included in the Colon cancer kit the
remaining 101/240 (42.1%) patients were considered RAS/BRAF
wild type.
The same protocol allowed the investigation of additional point
mutations occurring at the PIK3CA gene, albeit considered not
significant at present for therapy decision-making. We found
28/240 (11.7%) patients harbouring a PIK3CA mutation, alone
(9/28, 32.1%) or in conjunction with KRAS (15/28, 53.6%), NRAS
(3/28, 10.7%) or BRAF (1/28, 3.6%) mutations.
In 34 samples, we were not able to macrodissect tumour areas
for their enrichment at levels above 50% before DNA extraction. In
this subset of samples, somatic mutations of KRAS, NRAS and
BRAF demonstrated by Sequenom occurred in 16/34 (47.1%), 4/34
(11.8%), 1/34 (2.9%) specimens, respectively. The remaining
samples (38.2%) were considered wild type. Of note, the
distribution of somatic mutations was comparable (P40.05)
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between tumours above and below the 50% enrichment cutoff
(Figure 1B) and therefore it did not represent a possible bias.
Frequency distribution and clinicopathological features of
KRAS, NRAS, BRAF and PIK3CA mutated samples. KRAS was
confirmed as the most frequently mutated gene in our cohort. In
particular, the nucleotide substitutions affected codons 12, 13, 146
and 117 with decreasing frequency (Figure 1C). The most frequent
NRAS point mutations occurred at codons 12, 61 and 13
(Figure 1D). No exon 4 KRAS mutations were detected. BRAF
was mutated exclusively at codon 600 (p.V600E) (data not shown).
Finally, PIK3CA mutations mainly mapped to exon 9 (18/240,
7.5%), followed by exon 20 (8/240, 3.3%) (Figure 1E).
As reported in Table 1, the BRAF gene was confirmed
significantly associated with female gender (P¼ 0.013) and with
less differentiated (G3-G4) tumours (P¼ 0.013), as previously
reported (Loupakis et al, 2016). Node-negative patients resulted
more frequently mutated at codon 12 than 13 (P¼ 0.04). The
opposite occurred in tumours with pN2 nodal status (Po0.05;
Table 2). Among all RAS mutations, the p.G12V KRAS prevailed in
G3-G4 tumours, although this correlation did not reach statistical
significance (Table 3).
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Figure 1. Distribution of gene mutations and allelic variants occurring at KRAS, NRAS, BRAF and PIK3CA genes in tumour DNAs of mCRC
patients by Sequenom analysis. (A) Distribution of mutated (m) and wild-type (WT) specimens at exon 2 of KRAS, at exons 3 and 4 of KRAS, at
exons 2, 3 and 4 of NRAS and at codon 600 of BRAF. (B) Distribution of mCRC patients with tumour DNA sequences either WT or mutated (m) at
the KRAS, NRAS and BRAF genes, according to a tumour/normal cell ratio below (NA, not adequate) and above (A, adequate) the 50% cutoff.
Panels C–E represent the allelic variant distribution belonging to the mutated KRAS (C), NRAS (D) and PIK3CA (E) genes.
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Table 2. Distribution of KRAS mutations according to the involved hotspot gene sequences and to clinicopathological features
mKRAS n (%) mKRAS ex 2 n (%) mKRAS ex 3-4 n (%) mKRAS cod 12 n (%) mKRAS cod 13 n (%)
Sex
F 52 (46.0) 44 (44.9) 8 (47.0) 35 (46.7) 9 (42.9)
M 61 (54.0) 52 (55.1) 9 (53.0) 40 (52.3) 12 (57.1)
Subtotal 113 (100) 96 (100) 17 (100) 75 (100) 21 (100)
Age (years)
Median 64 64 65,5 64 63
Range 34–84 34–84 47–76 34–84 49–74
Subtotal 101 85 16 66 19
G
1–2 57 (73.1) 48 (73.8) 9 (69.2) 36 (72.0) 12 (80.0)
3–4 21 (26.9) 17 (26.2) 4 (30.8) 14 (28.0) 3 (20.0)
Subtotal 78 (100) 65 (100) 13 (100) 50 (100) 15 (100)
pT
1–2 5 (6.4) 4 (6.1) 1 (7.7) 3 (6.0) 1 (6.7)
3–4 73 (93.6) 61 (93.9) 12 (92.3) 47 (94.0) 14 (93.3)
Subtotal 78 (100) 65 (100) 13 (100) 50 (100) 15 (100)
pN
0 19 (25.0) 17 (26.6) 2 (16.7) 16 (32.6)a 1 (6.6)a
1 36 (47.4) 30 (46.8) 6 (50.0) 23 (46.9) 7 (46.7)
2 21 (27.6) 17 (26.6) 4 (33.3) 10 (20.4)a 7 (46.7)a
Subtotal 76 (100) 64 (100) 12 (100) 49 (100) 15 (100)
Vascular and/or perineural invasion
Yes 52 (75.4) 44 (75.9) 8 (72.7) 32 (74.4) 12 (80.0)
No 17 (24.6) 14 (24.1) 3 (27.3) 11 (25.6) 3 (20.0)
Subtotal 69 (100) 58 (100) 11 (100) 43 (100) 15 (100)
Abbreviations: m¼mutated; ex¼exon; cod¼ codon; F¼ female; M¼male.
aThe percentage of specimens KRASmutated at the codon 12 is significantly higher in the pN0 than in the pN2 tumours (Po0.05); the opposite occurs in specimens mutated at the codon 13 of
the KRAS gene.
Table 3. Distribution of the leading RAS gene mutations according to clinicopathological features
KRAS G12A
n (%)
KRAS G12C
n (%)
KRAS G12D
n (%)
KRAS G12V
n (%)
KRAS G13D
n (%)
KRAS A146T
n (%)
NRAS G12D
n (%)
Sex
F 7 (63.6) 3 (42.9) 14 (45.2) 11 (45.8) 8 (42.1) 2 (28.6) 4 (80.0)
M 4 (36.4) 4 (57.1) 17 (54.8) 13 (54.2) 11(57.9) 5 (71.4) 1 (20.0)
Subtotal 11 (100) 7 (100) 31 (100) 24 (100) 19 (100) 7 (100) 5 (100)
Age (years)
Median 60 64 63 64 63 63 63
Range 34–74 34–71 36–84 45–81 49–74 56–73 40–67
Subtotal 11 6 29 18 17 6 4
Tumour
Primary 7 (63.6) 6 (100) 23 (76.7) 18 (85.7) 17 (89.5) 6 (85.7) 3 (60.0)
Met 4 (36.4) 0 (0) 7 (13.3) 3 (14.3) 2 (11.5) 1 (14.3) 2 (40.0)
Subtotal 11 (100) 6 (100) 30 (100) 21 (100) 19 (100) 7 (100) 5 (100)
G
1–2 8 (80.0) 2 (66.7) 18 (81.8) 7(53.8) 10 (76.9) 4 (80.0) 1 (50.0)
3–4 2 (20.0) 1 (33.3) 4 (18.2) 6 (46.2)a 3 (23.1) 1 (20.0) 1 (50.0)
Subtotal 10 (100) 3 (100) 22 (100) 13 (100) 13 (100) 5 (100) 2 (100)
pN
0 3 (30.0) 1 (33.3) 8 (38.1) 4 (30.7) 1 (7.7) 1 (25.0) 0 (0)
1 5 (50.0) 2 (66.7) 8 (38.1) 6 (46.2) 7 (53.8) 1 (25.0) 1 (50.0)
2 2 (20.0) 0 (0) 5 (23.8) 3 (23.1) 5 (38.5) 2 (50.0) 1 (50.0)
Subtotal 10 (100) 3 (100) 21 (100) 13 (100) 13 (100) 4 (100) 2 (100)
Vascular and/or perineural invasion
Yes 8 (88.9) 2 (66.7) 13 (68.4) 7 (70.0) 10 (76.9) 3 (75.0) 1 (100)
No 1 (11.1) 1 (33.3) 6 (31.6) 3 (30.0) 3 (23.1) 1 (25.0) 0 (0)
Subtotal 9 (100) 3 (100) 19 (100) 10 (100) 13 (100) 4 (100) 1 (100)
Abbreviations: F¼ female; M¼male; Met¼metastasis.
aIn G3-G4 tumours the percentage of the KRASp.G12V (p.Gly12Val) mutated specimens compared to the alternative KRAS-mutated specimens is higher although statistically not significant
(P¼ 0.051).
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Fast COLD-PCR detection of RAS mutations with low mutant
allele frequency in candidate patients for anti-EGFR-based
therapies. We re-analysed KRAS by fast COLD-PCR in 30/96
samples with already identified exon 2 mutations, 40/43 samples
mutated either at exons 3-4 of KRAS or at NRAS or BRAF, and
96/101 wild-type. All KRAS exon 2 mutations by Sequenom were
confirmed. A total of 15 additional mutations were detected
(15/166, 9%), specifically 9/96 (9.4%), 1/15 (6.7%), 2/13 (15.4%)
and 3/12 (25.0%) in mCRC previously categorised by Sequenom as
wild-type or already mutated at KRAS (exons 3 and 4), NRAS or
BRAF (Figure 2). The range of mutant allele frequency (MAF) of
these subclonal mutations was comprised between 0.1% and 5%.
We were able to reanalyse 12/15 subclonally mutated samples
after UDG digestion. Results were reproduced in two out of 12
samples, both originally wild type by Sequenom, but harbouring a
mutation with a MAF 43% detected by fast-COLD-PCR. One
patient had a complex mutation at position c.33_34delTGinsCT
(p.A11_G12AC) and the other a mutation c.35G4T (p.G12V,
p.Gly12Val), both undetectable with the Sequenom assay. Overall
this leads to a frequency of true subclonal KRAS mutations of 1.2%
(2.1% of the Sequenom wild-type subgroup).
In the remaining 10/12 cases (nine below and one above 3%
MAF, respectively) the subclonal KRAS mutations either disap-
peared (9/12, including three cases harbouring a BRAF mutation)
or turned to a different sequence variant at low MAF (1/12). In the
latter case a possible mechanism of DNA damage other than
cytosine deamination cannot be excluded (Figure 3).
To deepen our analysis, in six patients originally showing
subclonal KRAS mutations detected in one representative sample by
fast COLD-PCR only, we investigated 6–7 more blocks per patient,
deriving from the primary tumour and/or regional lymph-node/
distant metastases, for a total of 40 samples. Without UGD pre-
treatment, 5/6 cases showed a spectrum of subclonal KRAS variants
detected in 12/40 of all analysed blocks, of which only one showed
the same DNA change originally detected in the representative
diagnostic sample. The large majority of PCR amplified DNAs
(83.3%) became KRAS wild-type and the remaining (16.7%) showed
new mutation sequences, following UDG treatment.
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Figure 2. Gene mutations according to the degree of assay sensitivities in 240 mCRC patients. Sequenom found 57.9% of specimens mutated at
RAS/BRAF (mRAS/BRAF), whereas 42.1% were wild-type (WT). A more sensitive fast COLD-PCR method recruited additional mutated sequences
in both wild-type samples and in mutated samples. In particular, 90.6% of the samples RAS/BRAFWT by Sequenom were confirmed by fast COLD-
PCR, whereas the remaining 9.4% of DNAs were mutated at KRAS exon 2 (ex 2) with a discrete not negligible (1–5%) or low (o1%) mutational load.
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Figure 3. The fate of subclonal KRAS mutations after pre-treatment of
tumour DNAs with UDG. DNAs belonging to 12/15 mCRC tumours,
resulted subclonally mutated at KRAS by fast COLD-PCR in absence of
UDG pre-treatment (UDG- column), had been re-analysed after UDG
digestion (UDGþ column), aimed to avoid PCR artifacts due to
formalin fixation injuries on DNA molecules. Eighty-three per cent of
the mutated (by fast COLD-PCR, UDG-) cases became WT or changed
allelic variant after UDG digestion (UDGþ ), thus demonstrating their
artefactual nature. Only in two tumours (17% of the cases) the
mutations were re-confirmed after UDG treatment (UDGþ ). Both
mutations had a mutant allele frequency43%. ND: not determined
cases (due to lack of residual DNA).
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Fast COLD-PCR detects the mutations G4T or G4A of KRAS
at the codons 12 and 13. In order of frequency, the most
represented artifactual mutations were c.35G4A (p.G12D,
p.Gly12Asp) and c.38G4A (p.G13D, p.Gly13Asp).
DISCUSSION
The present study (i) confirms the frequency of classical KRAS
mutations (exon 2) by Sequenom and evaluates the presence of
specific additional mutations, as required by the new international
guidelines, in a series of 240 mCRCs; (ii) validates fast COLD-PCR
method for the analysis of KRAS gene exon 2 and determines the
frequency of mutations with low MAF, detectable only using highly
sensitive assays; and (iii) reveals the likely artifactual nature of
KRAS mutations present at very low MAF in FFPE samples,
especially when below 3%.
The KRAS exon 2 mutation rate by Sequenom was 40%, in line
with reported data (Rosty et al, 2013) and with results previously
obtained by our group with assays of similar analytical sensitivities
(Mariani et al, 2015). Of note, the ‘extended RAS’ test revealed
additional mutations in 21.5% of patients who were previously
considered eligible to therapies with anti-EGFR molecules. There-
fore, these patients would not meet the criteria for eligibility to this
targeted therapy according to the new guidelines (Allegra et al,
2016). An additional 8.3% of eligible patients were mutated at
BRAF codon 600, a feature linked with a worse prognosis
independently of other clinical parameters (Palomba et al, 2016;
Richman et al, 2009; Souglakos et al, 2009; Therkildsen et al, 2014;
Tol et al, 2010).
The Sequenom assay also allowed to explore the prevalence of
PIK3CA mutations, which were identified in 11.7% of the patients,
similarly to what recently reported by Palomba et al (2016). In
contrast with data reported by Normanno et al (2015), we did not
observe a significant association between tumours with low KRAS
mutational load and co-occurrence of mutated PIK3CA sequences.
This discrepancy may stem from a technical reason, as Normanno
and colleagues used a targeted next-generation sequencing
approach to assess the PIK3CA mutational status. A recent meta-
analysis study has pointed out that PIK3CA mutations may be
detrimental for the response to anti-EGFR molecules, especially
those occurring at exon 20 (Huang et al, 2014). Nevertheless, this
trend needs to be confirmed in clinical trials.
When we put into context our molecular data with respect to
tumour features, we observed that node positive (pN2) compared
to node-negative tumours were preferentially mutated at codon 13
rather than 12, supporting the hypothesis of a more aggressive
behaviour of tumours mutated at codon 13. In line with this
assumption, Feng et al (2015) demonstrated that KRAS mutations
at codon 13 and pN2 stage are independent risk factors for distant
metachronous metastases.
Interestingly, by deepening our analysis with fast COLD-PCR,
we detected up to the 0.1% of mutant/wild-type DNA molecules
and demonstrated that B10% of patients was found to harbour
KRAS exon 2 mutations with low mutant allele frequency among
BRAF wild-type individuals and supposed to be responsive to anti-
EGFR antibodies (RAS wild-type by standard assays).
These data are in line with those reported by the CRYSTAL
study analysing mCRC patients treated with fluorouracil, leucov-
orin and irinotecan with or without cetuximab. When tumour
DNA sequences of the CRYSTAL series were analysed using a 5%
mutant/wild-type cutoff, 14.7% of wild-type KRAS exon 2 patients
revealed point mutations at the ‘extended RAS’ sequences. The
same authors also observed that point mutations other than those
occurring at exon 2 of KRAS (extended RAS) play an adverse role
on progression-free and overall survival and objective responses
(Van Cutsem et al, 2015). The frequency of positive samples
increased up to 34.6% using an assay with a 0.1% sensitivity cutoff.
Although displaying a detectable level of mutation (0.1–5%), these
tumours were not associated with worse clinical responses.
Regrettably, the patients harbouring a KRAS mutation with low
MAF in our study were heterogeneously treated, thus precluding
any clinical correlations.
Nevertheless, given that formalin fixation is known to produce
several DNA injuries (Do and Dobrovic, 2015; Do et al, 2013;
Lamy et al, 2011), including deamination of the cytosine to uracil
which generates artifactual C:G4T:A changes, in our study we also
investigated the nature of these subclonal KRAS mutations by pre-
treating DNAs with UDG. This enzyme removes uracil bases
belonging to cytosine deamination and creates disruptions along
DNA sequence interfering with the PCR amplification of the
artifactual mutated sequences only. Following UDG digestion
results were reproduced in two cases only, both originally wild-type
by Sequenom and found to harbour mutations with a MAF 43%
by fast-COLD-PCR. This finding leads to a frequency of true
subclonal KRAS mutations of 2.1% of the Sequenom wild-type
tumours.
This evidence on artifactual DNA changes in FFPE samples is of
utmost importance, as recently the somatic mutation load has been
critically reviewed to determine the association with response or
resistance to specific targeted therapies (Dono et al, 2013; Molinari
et al, 2011; Van Cutsem et al, 2015). One may wonder which level
of mutational load is to be considered clinically predictive of
responsiveness/resistance to a specific targeted therapy. Several
groups have identified KRAS mutations harbouring low MAFs in
mCRC patients (Dono et al, 2013; Kimura et al, 2012; Laurent-Puig
et al, 2015; Molinari et al, 2011; Normanno et al, 2015; Tougeron
et al, 2013; Van Cutsem et al, 2015) (Supplementary Table 1);
however, distinct cutoffs to define minor subclones have been
adopted, heterogeneous cohorts (selected or unselected patients)
were analysed and details about the use of UDG pre-treatment
were not reported, thus leading to results that are difficult to
compare. Nevertheless, based on our data and on results of other
studies (Laurent-Puig et al, 2015; Normanno et al, 2015; Tougeron
et al, 2013), a MAF range comprised between 1 and 3% seems to
emerge as a grey area of mutational loads either with or without
clinical significance. Indeed, Tougeron et al (2013) were able to
show that presence of mutations with a MAF 42.3% was
associated with cetuximab resistance and shorter progression-free
survival. Likewise, Normanno et al (2015) reported a shorter
survival for those patients with a tumour harbouring KRAS
mutations with a MAF 43%. Of note, Laurent-Puig et al (2015)
observed that patients with less than 1% of KRAS MAF showed
similar progression-free survival and overall survival than those
with wild-type KRAS tumours, thus suggesting that patients with
mCRC with KRAS-mutated subclones (at least those with a KRAS-
mutated subclones fraction lower or equal to 1%) had a benefit
from anti-EGFR therapies.
Taken together these data suggest that subclonal mutations with
a very low MAF have to be taken with caution and further analysed
by including an UDG digestion step in the process to truly identify
mutations governing the choice of a therapeutic compound. This is
also of importance for an accurate mutational tracking of patients
exhibiting emergence of KRAS-mutated clones in their plasma
during anti-EGFR treatments.
In conclusion, our work further highlights that mCRCs are
rather heterogeneous showing coexisting multiple gene mutations,
with a small subset of patients (2.1% of the Sequenom wild-type
tumours) harbouring KRAS mutations missed due to intrinsic
limitations of the assay (in terms of sequence coverage and
technical sensitivity). In addition, we also unveil the occurrence of
artifactual mutations especially when MAFs are below 3%: this
evidence strongly supports the importance of UDG pre-treatment
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of DNA samples from FFPE to confirm the presence of true DNA
changes. Especially in the context of multicenter clinical trials, a
proper assessment of pathogenic mutations harboured by tumour
subclones (that is, intratumour heterogeneity) is warranted to
better understand their biological significance and clinical impact,
in terms of response to anti-EGFR molecules and targeted
therapies in general.
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